Kura Oncology Inc(KURA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:01 PM ET (Korea 10/29 05:01)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.36 | Insider Own | 2.78% | Shs Outstand | 89.0M | Perf Week | 8.65% |
| Market Cap | 0.95B | Forward P/E | - | EPS next Y | 25.35% | Insider Trans | -2.12% | Shs Float | 86.5M | Perf Month | -0.65% |
| Enterprise Value | 0.46B | PEG | - | EPS next Q | -0.82 | Inst Own | 100.83% | Short Float | 16.56% | Perf Quarter | 15.31% |
| Income | -0.30B | P/S | 12.37 | EPS this Y | -2.12% | Inst Trans | 3.5% | Short Ratio | 7.71 | Perf Half Y | 22.69% |
| Sales | 0.08B | P/B | 19.72 | EPS next 5Y | 15.25% | ROA | -46.73% | Short Interest | 14.32M | Perf YTD | 3.32% |
| Book/sh | 0.54 | P/C | 1.84 | EPS past 3/5Y | -16.16% -13.48% | ROE | -167.71% | 52W High | -22.77% ($13.90) | Perf Year | 2.14% |
| Cash/sh | 5.83 | P/FCF | - | Sales past 3/5Y | - | ROIC | -440.46% | 52W Low | 45.91% ($7.36) | Perf 3Y | 40.14% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -48.89% | Gross Margin | 97.6% | Volatility(W/M) | 3.85% 4.57% | Perf 5Y | -36.48% |
| Dividend TTM | - | EV/Sales | 5.96 | Sales Y/Y TTM | -7.27% | Oper. Margin | -411.9% | ATR (14) | 0.52 | Perf 10Y | 146.78% |
| Dividend Ex-Date | - | Quick Ratio | 4.71 | EPS Q/Q | -1.87% | Profit Margin | -384.3% | RSI (14) | 55.95 | Recom | 1.19 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.73 | Sales Q/Q | 36.54% | SMA20 | 6.39% ($10.09) | Beta | 0.55 | Target Price | $31.85 |
| Payout | - | Debt/Eq | 0.5 | Earnings | 2026/8/12 | SMA50 | -4.33% ($11.22) | Rel Volume | 1.23 | Prev Close | $9.9 |
| Employees | 260 | LT Debt/Eq | 0.39 | EPS/Sales Surpr. | 12.23% 3.53% | SMA200 | 9.6% ($9.79) | Avg Volume(3M) | 1.86M | Price | $10.73 |
| IPO | 2015/9/16 | Option/Short | Yes/Yes | Trades | 13368 | Volume | 2,283,973 | Change | 8.43% |
🧬 Kura Oncology (KURA) is a US biotech company developing precision oncology therapeutics that target both hematologic cancers and solid tumors. Its lead asset is the menin inhibitor ziftomenib, aimed at treating relapsed or refractory NPM1-mutant acute myeloid leukemia. Through joint development with a partner, the company is advancing toward commercialization and expanding its presence in the targeted oncology space.
Over the past 1 year, roughly in the middle
23% below its 1-year high.
Traded about as much as usual. That is 123% of its average volume.
KURA has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -2.1% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,237. Peers typically go for $1,261.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -36.5%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 100.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #161 of 594 in the industry
Based on market cap of $955M.
ORIC#160 ORIC Pharmaceuticals Inc $964M PER - KURA#161 Kura Oncology Inc $955M PER - 
ALMS#162 Alumis Inc $952M PER - 
RIGL#163 Rigel Pharmaceuticals $949M PER 3.1 
ODTX#164 Odyssey Therapeutics Inc $939M PER - 
FAQ
What kind of company is KURA?
KURA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of KURA?
The market cap of KURA is approximately $955M, ranking 2,621 within its sector.
What is the 52-week high and low for KURA?
KURA has recorded a 52-week high of $13.90 and a low of $7.36.
